Evoke Pharma Inc. (NASDAQ:EVOK) shot up 1.9% on Wednesday . The stock traded as high as $2.12 and last traded at $2.11, with a volume of 208,695 shares traded. The stock had previously closed at $2.07.

Several brokerages have weighed in on EVOK. Noble Financial reaffirmed a “hold” rating on shares of Evoke Pharma in a research report on Tuesday, August 16th. Northland Securities lowered Evoke Pharma from an “outperform” rating to a “market perform” rating in a research report on Monday, July 18th. HC Wainwright set a $2.50 target price on Evoke Pharma and gave the stock a “hold” rating in a research report on Tuesday, August 16th. Zacks Investment Research raised Evoke Pharma from a “hold” rating to a “buy” rating and set a $5.50 target price on the stock in a research report on Tuesday, May 3rd. Finally, Feltl & Co. lowered Evoke Pharma from a “strong-buy” rating to a “sell” rating in a research report on Monday, July 18th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and two have issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $10.28.

The company’s 50-day moving average price is $3.71 and its 200 day moving average price is $4.62. The firm’s market cap is $24.33 million.

Evoke Pharma (NASDAQ:EVOK) last announced its quarterly earnings data on Monday, August 15th. The specialty pharmaceutical company reported ($0.41) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.43) by $0.02. On average, equities research analysts predict that Evoke Pharma Inc. will post ($1.25) EPS for the current fiscal year.

Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.